2366152-15-8
中文名称
化合物 RPT193
英文名称
Cyclobutanecarboxylic acid, 3-[(3R)-3-[1-[5-chloro-4-[[(1R)-1-(2,4-dichlorophenyl)ethyl]amino]-6-methyl-2-pyrimidinyl]-3-azetidinyl]-1-piperidinyl]-1-methyl-, trans-
CAS
2366152-15-8
分子式
C27H34Cl3N5O2
分子量
566.95
MOL 文件
2366152-15-8.mol
2366152-15-8 结构式
基本信息
中文别名
化合物 RPT193 英文别名
Cyclobutanecarboxylic acid, 3-[(3R)-3-[1-[5-chloro-4-[[(1R)-1-(2,4-dichlorophenyl)ethyl]amino]-6-methyl-2-pyrimidinyl]-3-azetidinyl]-1-piperidinyl]-1-methyl-, trans-物理化学性质
沸点706.9±70.0 °C(Predicted)
密度1.387±0.06 g/cm3(Predicted)
储存条件-20°C储存
酸度系数(pKa)4.09±0.20(Predicted)
形态Solid
颜色White to off-white
应用领域
用途一
Zelnecirnon, also known as RPT193, is a CCR4 antagonist that blocks the recruitment of Th2 cells in order to treat inflammatory diseases (taken orally). The Phase 1b trial, which was conducted in patients with atopic dermatitis, found that markable improvement occurred after 4 weeks with little side effects. A Phase 2 clinical trial is currently being conducted to evaluate the efficacy and safety of Zelnecirnon, with an expected end date of September 2023.